SOMERSET, N.J., March 11, 2016 (GLOBE NEWSWIRE) — MTBC (NASDAQ:MTBC), a leading provider of proprietary, healthcare information technology solutions today announced that its e-prescribing tool has been awarded the prestigious 2015 White Coat of Quality by Surescripts for clinical quality excellence in e-prescribing.

This award, which MTBC has achieved three times, bolsters its e-prescribing products and highlights its commitment to continue to train its users. “MTBC is pleased to have been awarded this recognition by Surescripts,” said Hadi Chaudhry, MTBC Chief Information Officer. He added, “MTBC’s development team is devoted to building quality solutions that assist providers in their practice and this recognition is evidence of that commitment.”

This achievement recognizes MTBC for upholding the highest standards of prescription content quality in e-prescribing. In addition, this year MTBC released its pioneering electronic prescribing Smartwatch app for Apple Watch users.  Including this new app, MTBC now has over seven other mHealth apps in its suite. One of the most popular apps continues to be the MTBC ICD-10 converter app, which has consistently been the converter app of choice for providers across the nation, available for both Android and Apple devices.

To learn more about MTBC, please visit

About Medical Transcription Billing, Corp.

Medical Transcription Billing, Corp. is a healthcare information technology company that provides a fully integrated suite of proprietary web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. Our integrated Software-as-a-Service (or SaaS) platform helps our customers increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. MTBC’s common stock trades on the NASDAQ Capital Market under the ticker symbol “MTBC,” and its Series A Preferred Stock trades on the NASDAQ Capital Market under the ticker symbol “MTBCP.”

For additional information, please visit our website at


Press Contact:
Amritpal Deol, 
Vice President and General Counsel
(732) 873-5133 x 141

Primary Logo